PRAME and sarcoma: PRAME is a potential target for the development of cellular immunotherapies in sarcoma (mEL 4)37, while in medulloblastoma, preclinical studies have shown the efficacy of adoptive immunotherapy with PRAME-specific T cells (mEL 3)38.